Skip to main content
Addgene

pCMV-T7-BPNLS-CE-ABE8e-SpCas9(D10A)-BPNLS-P2A-EGFP (NK350)
(Plasmid #208292)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 208292 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pCMV-T7-ABE8e-nSpCas9-P2A-EGFP (KAC978)
  • Backbone manufacturer
    Benjamin Kleinstiver (Addgene plasmid # 185910)
  • Vector type
    Mammalian Expression, CRISPR ; in vitro transcription; T7 promoter

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    pCMV-T7-BPNLS-CE-ABE8e-SpCas9-BPNLS-P2A-EGFP
  • Alt name
    NK350
  • Alt name
    CE-ABE8e-SpCas9
  • Species
    Synthetic
  • Mutation
    ABE8e mutations in TadA inlaid into nSpCas9(D10A)
  • Promoter CMV and T7
  • Tags / Fusion Proteins
    • BPNLS (N terminal on insert)
    • BPNLS-P2A-EGFP (C terminal on insert)

Cloning Information

  • Cloning method Gibson Cloning
  • 5′ sequencing primer oBK6928-CCAAGTCTCCACCCCATTGACG
  • 3′ sequencing primer oBK219-GGGAGTGGCACCTTCCAGGGTC
    • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pCMV-T7-BPNLS-CE-ABE8e-SpCas9(D10A)-BPNLS-P2A-EGFP (NK350) was a gift from Benjamin Kleinstiver (Addgene plasmid # 208292 ; http://n2t.net/addgene:208292 ; RRID:Addgene_208292)

  • For your References section:

    Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. Alves CRR, Ha LL, Yaworski R, Sutton ER, Lazzarotto CR, Christie KA, Reilly A, Beauvais A, Doll RM, de la Cruz D, Maguire CA, Swoboda KJ, Tsai SQ, Kothary R, Kleinstiver BP. Nat Biomed Eng. 2023 Dec 6. doi: 10.1038/s41551-023-01132-z. 10.1038/s41551-023-01132-z PubMed 38057426
Related items: